Drugs / rMenB+OMV NZ
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT03587207 Comparator | Jul → Dec 2018 | meningococcal meningitis | GlaxoSmithKline | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | rMenB+OMV NZ | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03587207 ↗ |
| Known as | Bexsero | “rMenB+OMV NZ (Bexsero) vaccine” NCT03587207 ↗ |